Polypharmacy and clinical outcomes in geriatric patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor pathway inhibitors
{{output}}
ObjectiveThis study aimed to evaluate the prevalence of polypharmacy and its association with clinically significant adverse events in geriatric patients (≥65 years) with metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen receptor pathway... ...
